KVUE Kenvue Inc.

$17.34

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Kenvue, Inc. (KVUE) is poised for its upcoming earnings announcement on October 23, 2025, with market watchers keenly observing whether the company can surpass the whisper number of $0.27 EPS, slightly above the consensus estimate of $0.26. This subtle yet significant difference underscores the market's cautious optimism about Kenvue's ability to leverage its strategic initiatives effectively. With a robust market cap of approximately $31.95 billion, Kenvue's anticipated revenue of $3.82 billion will be a critical indicator of its operational strength and market positioning. The absence of recent news leaves investors focusing on Kenvue's historical performance and strategic execution as they assess its potential to meet or exceed expectations. As the earnings date approaches, the key question remains whether Kenvue can deliver results that align with the market's quiet confidence, as reflected in the whisper number, and continue to build on its financial foundation.

Updated On 12/31/2025

About Kenvue Inc.

Kenvue Inc. is a consumer health company globally.

Website: https://www.kenvue.com

Sector
LIFE SCIENCES
Industry
PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1944048
Address
199 GRANDVIEW ROAD, SKILLMAN, NJ, UNITED STATES
Valuation
Market Cap
$44.88B
P/E Ratio
43.31
PEG Ratio
2.39
Price to Book
4.64
Performance
EPS
$0.54
Dividend Yield
3.51%
Profit Margin
6.67%
ROE
9.87%
Technicals
50D MA
$22.76
200D MA
$21.91
52W High
$24.36
52W Low
$17.18
Fundamentals
Shares Outstanding
2B
Target Price
$24.21
Beta
nan

KVUE EPS Estimates vs Actual

Estimated
Actual

KVUE News & Sentiment

Dec 31, 2025 • MarketBeat NEUTRAL
Renaissance Capital LLC Acquires 351,259 Shares of Kenvue Inc. $KVUE
Renaissance Capital LLC significantly increased its stake in Kenvue Inc. (NYSE:KVUE) during the third quarter, acquiring 351,259 additional shares to hold a total of 980,436 shares, now making KVUE its second-largest position. This move follows other institutional investors adjusting their holdings and precedes a notable insider purchase by Director Jeffrey C. Smith. Kenvue's stock currently has an average "Hold" rating from analysts with a target price of $20.23, and it offers a 4.8% dividend yield.
Dec 30, 2025 • Finviz NEUTRAL
Kimberly-Clark (KMB) Target Lowered as Citi Rebalances Household Care View
Citi lowered its price target on Kimberly-Clark Corporation (KMB) to $95 from $100 while maintaining a Sell rating, shifting its focus towards household and personal care companies for 2026. This rebalance comes as inventory destocking concludes, and consumption comparisons ease. Kimberly-Clark is also expanding its manufacturing in Vietnam and acquiring Kenvue, expecting significant cost synergies and growth in digital engagement.
Dec 30, 2025 • MSN SOMEWHAT-BULLISH
Mixed options sentiment in Kenvue Inc with shares up 0.38%
This article, though having an incomplete content, indicates that Kenvue Inc (KVUE) has experienced a slight increase of 0.38% in its shares. The headline also suggests a mixed sentiment among options traders for the company.
Dec 29, 2025 • Barchart.com NEUTRAL
Activist Investor Toms Capital Is Buying Up Target Stock. Should You?
Activist hedge fund Toms Capital Investment Management (TCIM) has acquired a significant stake in Target Corporation (TGT), signaling potential pressure for strategic changes following Target's prolonged underperformance and sales slowdown. Despite a recent stock boost from the news, Target's shares are down over 27% year-to-date, reflecting continued challenges like cautious consumer spending and weak discretionary demand. Analysts maintain a cautious "Hold" rating on TGT stock, awaiting evidence of sustained growth before a re-rating.
Dec 29, 2025 • NJBIZ SOMEWHAT-BEARISH
Johnson & Johnson ordered to pay $1.5B in baby powder case
A Baltimore jury has ordered Johnson & Johnson to pay over $1.5 billion to a Maryland woman who developed mesothelioma, an incurable cancer, after decades of using the company's talc-based baby powder. The verdict includes $59.84 million in compensatory damages and $1.5 billion in punitive damages, making it one of the largest verdicts against J&J for a single plaintiff. J&J plans to appeal, maintaining its talc products are safe and do not cause cancer, while also facing tens of thousands of other lawsuits regarding its talc products.
Dec 29, 2025 • MarketBeat NEUTRAL
Norris Perne & French LLP MI Reduces Stock Holdings in Kenvue Inc. $KVUE
Norris Perne & French LLP MI decreased its stake in Kenvue Inc. by 25.1% in Q3, selling 178,615 shares and retaining 531,799 shares valued at approximately $8.63 million. This reduction comes amid varied institutional investor activity and a mixed Wall Street sentiment, with several analysts setting a "Hold" rating and an average price target of $20.23 for KVUE. Despite the reduction by Norris Perne & French, a director, Jeffrey C. Smith, significantly increased his holdings by purchasing 3.2 million shares for over $55 million.
Sentiment Snapshot

Average Sentiment Score:

0.091
50 articles with scored sentiment

Overall Sentiment:

Neutral

KVUE Reported Earnings

Aug 07, 2025
Jun 30, 2025 (Pre market)
0.01 Surprise
  • Reported EPS: $0.29
  • Estimate: $0.28
  • Whisper:
  • Surprise %: 3.6%
May 08, 2025
Mar 31, 2025 (Pre market)
0.01 Surprise
  • Reported EPS: $0.24
  • Estimate: $0.23
  • Whisper:
  • Surprise %: 4.3%
Feb 06, 2025
Dec 31, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $0.26
  • Estimate: $0.26
  • Whisper:
  • Surprise %: 0.0%
Nov 07, 2024
Sep 30, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $0.28
  • Estimate: $0.27
  • Whisper:
  • Surprise %: 3.7%
Aug 06, 2024
Jun 30, 2024 (Pre market)
0.04 Surprise
  • Reported EPS: $0.32
  • Estimate: $0.28
  • Whisper:
  • Surprise %: 14.3%
May 07, 2024
Mar 31, 2024 (Pre market)
0.03 Surprise
  • Reported EPS: $0.28
  • Estimate: $0.25
  • Whisper:
  • Surprise %: 12.0%
Feb 08, 2024
Dec 31, 2023 (Pre market)
0.03 Surprise
  • Reported EPS: $0.31
  • Estimate: $0.28
  • Whisper:
  • Surprise %: 10.7%
Oct 26, 2023
Sep 30, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $0.31
  • Estimate: $0.31
  • Whisper:
  • Surprise %: 0.0%
Jul 20, 2023
Jun 30, 2023 (Pre market)
0.02 Surprise
  • Reported EPS: $0.32
  • Estimate: $0.30
  • Whisper:
  • Surprise %: 6.7%

Financials